Related Experiment Video

Updated: May 16, 2026

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
10:26

Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes

Published on: January 16, 2015

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation

Wei Qi1, HoMan Chan, Lin Teng

  • 1China Novartis Institutes for BioMedical Research, Shanghai 201203, China.

Proceedings of the National Academy of Sciences of the United States of America
|December 14, 2012
PubMed

Insights

Enhancer of zeste homolog 2 (Ezh2) enzyme activity drives cancer growth. A new inhibitor, EI1, blocks Ezh2, reducing tumor cell proliferation and causing apoptosis, validating Ezh2 as a therapeutic target.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Ezh2 is a key component of Polycomb repressive complex 2 (PRC2).
  • PRC2 regulates gene expression via histone H3 lysine 27 methylation (H3K27).
  • Ezh2 mutations are implicated in lymphomas, suggesting its role in cancer.

Purpose of the Study:

  • To investigate the role of Ezh2 enzymatic activity in tumor growth.
  • To develop and evaluate a selective small molecule inhibitor of Ezh2.

Main Methods:

  • Development of a potent and selective Ezh2 inhibitor, EI1.
  • Treatment of lymphoma cells with EI1.
  • Assessment of H3K27 methylation, gene expression, cell proliferation, cell cycle, and apoptosis.

Main Results:

  • EI1 directly binds and inhibits Ezh2 enzymatic activity.
  • EI1 treatment leads to genome-wide H3K27 demethylation and PRC2 target gene activation.
  • EI1 reduces proliferation, induces cell cycle arrest, and promotes apoptosis in Ezh2-mutated lymphoma cells.

Conclusions:

  • Ezh2 enzymatic activity is crucial for lymphoma cell growth.
  • EI1 effectively inhibits Ezh2 and demonstrates anti-cancer effects.
  • Ezh2 is a promising therapeutic target for cancer treatment.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.